Top 10 Deals of 2024: Maven Clinic Announces $125 Million Series F

This week, we dive into Maven Clinic's recent $125 million Series F funding round and explore how this milestone sets the stage for a new era of innovation in women's and family health.

Maven’s successful raise marks one of a few sizable late-stage women’s health deals in 2024, underscoring the impressive growth potential of companies innovating in women’s health and paving the way for earlier-stage companies to follow suit.

In early October, Maven Clinic, the world’s largest virtual clinic specializing in women’s and family health, secured $125 million in Series F funding. The deal was led by StepStone Group with participation from notable investors like General Catalyst, Sequoia, Oak HC/FT, and Lux Capital, bringing Maven’s total funding to over $425 million. This funding supports Maven’s mission to expand its reach and enhance healthcare accessibility for women and families worldwide.

Acting as both a care coordinator and provider, Maven connects users to specialists—from OB-GYNs and nutritionists to mental health experts, reproductive endocrinologists, sleep coaches, lactation consultants, and parenting advisors—while coordinating seamless care across diverse needs. Through video consultations, online resources, and chat services, Maven removes geographical barriers, enabling individuals to access top-tier care from home.

By partnering with employers and health plans, Maven integrates its services into employee benefits, helping organizations boost employee well-being and potentially lower healthcare costs. As a global platform covering the entire reproductive life cycle, Maven is trusted by over 2,000 companies in 175 countries, including Amazon, Microsoft, AT&T, Morgan Stanley, and L’Oreal. Additionally, Maven offers direct-to-consumer options, ensuring flexible access to specialized care for anyone in need.

Other VC-backed women’s health players that provide supplemental services to traditional health insurance offerings include:

Progyny, Public: Fertility benefits manager, working with a wide network of clinics and providing tailored care. They emphasize a personalized approach, assigning patient advocates to guide users through their fertility journey​.

Canopie, Seed: Canopie's evidence-based approach improves maternal mental health outcomes by making care accessible, creating cost savings.

Midi, Series B: Midi partners with payors and employers to offer virtual, personalized healthcare specifically for women navigating perimenopause, menopause, and related health transitions.

Carrot Fertility, Series C: Fertility benefits manager for employers, focusing on inclusivity and personalized care.

The emergence of digital health platforms has made it possible to supplement traditional health insurance offerings, providing virtual, personalized care that addresses the unique journeys of women and families. As the sector evolves, the collective effort to prioritize women's health will undoubtedly shape the future of healthcare, fostering a more inclusive environment for families around the world.

Continue Reading

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Top 10 Deals of 2024: Hologic Acquires Uterine Fibroid Treatment Company for $350M

This blog assesses a recent women’s health deal that expands treatment options for uterine fibroids and abnormal uterine bleeding. These indications are infrequently discussed and therefore unfamiliar to many, yet impact a significant number of women, especially those in perimenopause.

Top 10 Deals of 2024: Viatris sells Women's Health Line in $1.2B Deal

This week we delve into a major acquisition touching multiple areas of women’s health. A deal like this demonstrates a strong appetite for women’s health innovation, across indications, as acquirers recognize the financial viability in meeting these needs.

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Top 10 Deals of 2024: Hologic Acquires Uterine Fibroid Treatment Company for $350M

This blog assesses a recent women’s health deal that expands treatment options for uterine fibroids and abnormal uterine bleeding. These indications are infrequently discussed and therefore unfamiliar to many, yet impact a significant number of women, especially those in perimenopause.

Fast track our industry.
Get in touch today.